Goldman Sachs Maintains Top Rating on Edwards Lifesciences (EW), But Trims Numbers

Goldman Sachs reiterated their Conviction Buy-List rating on Edwards Lifesciences (NYSE: EW) but trimmed their price target from $90 to $88.

At this point shares of EW are trading trading slightly above the implied value should PARTNER A (P-A) not gain approval ($64). However, the firm continues to see P-A gaining approval, with timing being the issue. Longer-term they said the new product mix should drive EPS growth 2-3X faster than revenue.

Goldman lowered estimates and its price target to reflect a delay in US P-A approval.

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $68.53 yesterday.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Canaccord Genuity Downgrades Antofagasta Plc. (ANTO:LN) (ANFGF) to Hold
• JPMorgan Upgrades STO Express Co Ltd (002468:CH) to Neutral
• Raymond James Upgrades Kratos Defense & Security (KTOS) to Strong Buy